KLRA

KLRA remains in a confirmed Stage 4 decline, trading below downward-sloping EMAs with a clear sequence of lower highs and lower lows. The medium-term bias is bearish and mean-reversion entries are not permitted, but extreme oversold readings and a small exhaustion bounce discourage immediate selling. We prefer to trim into rallies toward the 9/21/50 EMA confluence and recent swing highs around the 20.5–21.0 area, targeting rejection at those levels.

• ↑Novel oral GLP-1 agonist HRS-7535 targets obesity and diabetes
• ↑Institutional ownership >90% indicates strong backer confidence
• ↓Shares fell over 10% after trial data disappointed